Im Sortiment seit:
Baker, Laurence H.
Corbett, Thomas H.
Valeriote, Frederick A.
HC runder Rücken kaschiert
The focus of the 22nd Annual Detroit Cancer Symposium was the presentation and discussion of cytotoxic agents, with a significant portion of the symposium including the exciting frontiers of drug discovery being explored by the National Cooperative Drug Discovery Groups (NCDDG) Program. The symposium brought together a large number of investigators from government, universities and pharmaceutical companies involved in the discovery and development of new anticancer agents. Exciting new leads were presented and the status of others presently under development was discussed.
Of particular significance has been the initiation of renewed efforts in the area of natural product drug discovery, where the discovery of new cytotoxics is very promising at the moment. A number of major changes have occurred during the last decade in research on drug discovery of cytotoxic agents. Critical reviews of a number of the models and concepts underlying drug discovery represented a continuous thread throughout the meeting, being constantly discussed in terms of their advantages, disadvantages and capabilities of discovering solid tumor active anticancer agents.
A recent development which is to be much applauded and which portends to great discoveries is the new relationship formed between Government, University of Industry. The NCDDG mechanism which stimulates this interaction is an inexpensive manner to greatly magnify the drug discovery and development effort nationally. Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development represents a forum which will become the major mode for bringing together these three different components in the equation to regularly discuss new results and ideas.
1. DRUG DISCOVERY- 1990.- 2. DATA DISPLAY AND ANALYSIS STRATEGIES FOR THE NCI DISEASE-ORIENTED IN VITRO ANTITUMOR DRUG SCREEN.- 3. DISCOVERY OF SOLID TUMOR ACTIVE AGENTS USING A SOFT-AGAR-COLONY-FORMATION DISK-DIFFUSION- ASSAY.- 4. THYMIDYLATE SYNTHASE INHIBITION OF MODIFIED QUINAZOLINE ANTIFOLATES.- 5. DNA-MINOR GROOVE BINDING ANTICANCER AGENTS.- 6. 2-((ARYLMETHYL)AMIN0)-l,3-PR0PANEDI0LS (AMAPS); DISCOVERY, SELECTION AND DEVELOPMENT OF FOUR CLINICAL CANDIDATES.- 7. MECHANISM-BASED APPROACHES TO CANCER DRUG DISCOVERY.- 8. DISCOVERY AND BULK PRODUCTION OF NATURAL PRODUCTS WITH ANTICANCER ACTIVITY: THE ROLE OF CHEMICAL ECOLOGY.- 9. CHEMICAL APPROACHES TO IMPROVED RADIOTHERAPY.- 10. LARGE SCALE ANTICANCER DRUG SCREENING AT STERLING DRUG INC..- 11. ARE ANTISENSE OLIG0NUCLEOTIDES THERAPEUTIC AGENTS OF THE FUTURE?.- 12. SUPERCOMPUTER AIDED DRUG DESIGN: APPLICATION IN ONCOLOGY AND AIDS.- 13. EXTRACHROMOSOMAL DNA AS A TARGET FOR DRUG DEVELOPMENT.- 14. PROSPECTIVE EVALUATION OF A PREDICTIVE MODEL FOR PLASMA CONCENTRATION-VERSUS-TIME PROFILES OF INVESTIGATIONAL ANTICANCER DRUGS IN PATIENTS.- 15. AGENT-DIRECTED PRECLINICAL TOXICOLOGY FOR NEW ANTINFOPLASTIC DRUGS.- 16. PRECLINICAL STUDIES WITH BREQUINAR SODIUM: A NOVEL ANTICANCER AGENT.- 17. DIPHTHERIA TOXIN-RELATED PEPTIDE HORMONE FUSION PROTEINS: NEW TOXINS WITH THERAPEUTIC POTENTIAL.- 18. ANTI-GROWTH FACTOR RECEPTOR ANTIBODIES AS THERAPY FOR CANCER.- 19. REGULATION OF POLYAMINE BIOSYNTHETIC ACTIVITY AND HOMEOSTASIS AS A NOVEL ANTIPROLIFERATIVE STRATEGY.- 20. ESPERAMICIN A1 (BMY28175)- A NOVEL ANTI- TUMOR AGENT OF THE DIYNE-ENE CLASS.- 21. MODIFIED 2-TUMOR (L1210, COLON 38) ASSAY TO SCREEN FOR SOLID TUMOR SELECTIVE AGENTS.- 22. 5-FLUOROURACIL: SCHEDULE OPTIMIZATION IN METASTATIC COLORECTAL CANCER.- 23. PRECLINICAL ANTITUMOR EFFICACY OF TAXOTERE (RP56976, NSC 628503), A TAXOL ANALOG AND OF RP60475 (NSC645008), A NEW BENZOPYRI- DOINDOLE.